Fibroscan and Low-Density Lipoprotein Versus Non-invasive Markers (APRI test and FIB-4) As Determinants of Severe Liver Fibrosis in Egyptian Diabetic Patients With Non-Alcoholic Fatty Liver Disease
Esmail, E., Elnadry, M., Hegazy, M., Abdelhalim, M., Barbari, M. (2644). Fibroscan and Low-Density Lipoprotein Versus Non-invasive Markers (APRI test and FIB-4) As Determinants of Severe Liver Fibrosis in Egyptian Diabetic Patients With Non-Alcoholic Fatty Liver Disease. EKB Journal Management System, 2023(1), -. doi: 10.58675/2682-339X.1874
Esmail Anwar Esmail; Mohamed Hassan Elnadry; Mohamed Mousa Hegazy; Mohamed Mahmoud Abdelhalim; Mohamed Hassani Barbari. "Fibroscan and Low-Density Lipoprotein Versus Non-invasive Markers (APRI test and FIB-4) As Determinants of Severe Liver Fibrosis in Egyptian Diabetic Patients With Non-Alcoholic Fatty Liver Disease". EKB Journal Management System, 2023, 1, 2644, -. doi: 10.58675/2682-339X.1874
Esmail, E., Elnadry, M., Hegazy, M., Abdelhalim, M., Barbari, M. (2644). 'Fibroscan and Low-Density Lipoprotein Versus Non-invasive Markers (APRI test and FIB-4) As Determinants of Severe Liver Fibrosis in Egyptian Diabetic Patients With Non-Alcoholic Fatty Liver Disease', EKB Journal Management System, 2023(1), pp. -. doi: 10.58675/2682-339X.1874
Esmail, E., Elnadry, M., Hegazy, M., Abdelhalim, M., Barbari, M. Fibroscan and Low-Density Lipoprotein Versus Non-invasive Markers (APRI test and FIB-4) As Determinants of Severe Liver Fibrosis in Egyptian Diabetic Patients With Non-Alcoholic Fatty Liver Disease. EKB Journal Management System, 2644; 2023(1): -. doi: 10.58675/2682-339X.1874

Fibroscan and Low-Density Lipoprotein Versus Non-invasive Markers (APRI test and FIB-4) As Determinants of Severe Liver Fibrosis in Egyptian Diabetic Patients With Non-Alcoholic Fatty Liver Disease

Al-Azhar International Medical Journal
Volume 2023, Issue 1, January 2023  XML
DOI: 10.58675/2682-339X.1874
View on SCiNiTO View on SCiNiTO
Authors
Esmail Anwar Esmail1; Mohamed Hassan Elnadry1; Mohamed Mousa Hegazy1; Mohamed Mahmoud Abdelhalim1; Mohamed Hassani Barbari2
1Hpatology & Gastrontrology and Infectious Diseases, Faculty of Medicine - Al-Azhar University, Egypt
2National Hepatology and Tropical Medicine Research Institute (NHTMRI), Egypt
Abstract
Background: Type 2 Diabetes Mellitus (T2DM) cases commonly have non-alcoholic fatty liver disease (NAFLD) that can develop into severe liver fibrosis. Clinical implications might arise from the early detection of hepatic fibrosis. Aim of the study: to evaluate the role of non-invasive scores (APRI score and FIB-4), Fibroscan and low-density lipoprotein in predicting Egyptian patients with NAFLD who have severe liver fibrosis. Patients and methods: A prospective cohort study was carried out. in the heptogastroentrology and infectious disease Al-Hussien University Hospital and The National Hepatology and Tropical Research Institute (NHTMRI) over a 3-years period. Ninty patients attended the outpatient clinic who had NAFLD were enrolled in the study on aprospective basis, aged18 to 70 years old. Results: the cases was separated into two groups diabetic and non diabetic Concerning the correlation between APRI test and (FIB-4, fibrosis LSM, steatosis CAP, and lab tests show significant positive correlation as regard Fib-4, fibrosis Lsm, AST, and ALT, and significant negative correlation as regard platelet and FBS, and the relationship between Fib-4 and fibrosis LSM and steatosis CAP and lab tests show significant positive correlation as regard fibrosis LSM, Age, and AST, and significant negative correlation as regard platelets and urea. Conclusion: The combination of Fibroscan, APRI score,LDL-c and FIB-4 techniques gives a useful approach for evaluating liver fibrosis in NAFLD cases.
Statistics
Article View: 6